ClinVar Miner

Submissions for variant NM_004004.6(GJB2):c.425T>C (p.Phe142Ser)

gnomAD frequency: 0.00007  dbSNP: rs116769964
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000590488 SCV000698256 uncertain significance not provided 2017-05-16 criteria provided, single submitter clinical testing Variant summary: The GJB2 c.425T>C (p.Phe142Ser) variant involves the alteration of a conserved nucleotide and is predicted to be damaging by 4/4 in silico tools (SNPsandGO not captured due to low reliability index). This variant was found in 5/121060 control chromosomes from ExAC at a frequency of 0.0000413, which does not exceed the estimated maximal expected allele frequency of a pathogenic GJB2 variant (0.0003376). The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories, nor has it been evaluated for functional impact by in vivo/vitro studies. Two missense changes have been observed in this same codon in patients with NSHL: a do novo F142L variant in one patient (PMID: 14708631) and heterozygous F142I variant in another patient (PMID: 24645897). The phenylalanine at position 142, located in the third transmembrane, is evolutionarily conserved, as determined by ClustalW2 alignment among mammalian species. The loss of the orthologous phenylalanine residue might interfere with the -helical structure of the transmembrane and the proper topologies of GJB2 resulting in faster closure of gap junction channels and inhibition of signal propagation (discussed in PMID 24645897). These data suggests that this variant is possibly pathogenic. However, due to absence of clinical information and the lack of functional studies, this variant is currently classified as a variant of uncertain significance (VUS) until additional information becomes available.
GeneDx RCV000590488 SCV005371858 uncertain significance not provided 2023-07-07 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 25388846)
Labcorp Genetics (formerly Invitae), Labcorp RCV000590488 SCV005816548 uncertain significance not provided 2024-09-21 criteria provided, single submitter clinical testing This sequence change replaces phenylalanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 142 of the GJB2 protein (p.Phe142Ser). This variant is present in population databases (rs116769964, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with GJB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 496220). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt GJB2 protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Natera, Inc. RCV001829629 SCV002086046 uncertain significance Autosomal recessive nonsyndromic hearing loss 1A 2020-09-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.